BioSpace News Archive

HealthCare Royalty Partners (“HCR” or the “Firm”), a global healthcare investment firm with $5.5 billion of cumulative capital commitments, today announced the closing on $1.83 billion for HealthCare Royalty Partners IV, L.P. (“Fund IV”) and affiliated entities.

Karuna Therapeutics, Inc. announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics, will present at the 38th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA.

Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, announced that President and CEO Bill Hinshaw will be presenting at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on January 16, 2020 at 8:30 a.m. PT.

enGene Inc., the biotechnology company developing rationally designed gene therapies targeted to mucosal tissues through its proprietary non-viral vector DDX® platform, today announced the appointments of Sharon Tan as Vice President and Head of Program Management, and Lance Dieter as Vice President of CMC and Head of Manufacturing,

Selexis SA, a JSR Life Sciences Company, today announced the promotion of Yemi Onakunle, PhD, MBA, to the position of chief business officer.

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration 510(k) clearance for expanded indication of the Indigo® Aspiration System.

Sangamo Therapeutics, Inc., a genomic medicine company, announced that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16th at 8:30 a.m. PT in San Francisco.

CareCentrix, the leading provider of home-based post-acute care solutions, happily announces that it has been recognized by independent analysts at the Great Place to Work Institute with a certification as a 2019-2020 Great Place to Work.

BioDirection, Inc., a privately held medical device company developing cutting-edge and rapid point-of-care products for the objective diagnosis and management of concussion and other traumatic brain injuries, today announced that Jean-Luc Boulnois has joined the company’s Board of Directors.

Study to quantify changes in post-surgical treatment and impact of early relapse detection using Signatera test